Revolution Medicines director granted new stock awards
Revolution Medicines director Frank Clyburn reported receiving equity awards in the form of common stock and stock options.
Rhea-AI Filing Summary
Revolution Medicines director Frank Clyburn reported receiving equity awards in the form of common stock and stock options. He was granted 1,191 shares of Common Stock, increasing his direct holdings to 10,929 shares, and a separate grant of 3,127 Stock Options (Right to Buy) with a $162.99 exercise price, each option for one share of common stock.
The option grant will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next annual meeting following the grant date, as long as he remains a Service Provider under the company’s 2020 Plan through that vesting date. The filing also notes that his holdings include 4,080 restricted stock units, which typically convert into shares over time.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 4,318 shares
Grant/Award
2 txns
Insider
Clyburn Frank
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 3,127 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 1,191 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 3,127 contracts (Direct);
Common Stock — 10,929 shares (Direct)
Footnotes (2)
- F1. Includes 4,080 restricted stock units.
- F2. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.
Key Figures
Common stock award: 1,191 shares
Director holdings after award: 10,929 shares
Stock options granted: 3,127 options
+3 more
6 metrics
Common stock award
1,191 shares
Grant of Common Stock on June 18, 2026
Director holdings after award
10,929 shares
Total direct Common Stock holdings following transactions
Stock options granted
3,127 options
Stock Option (Right to Buy) award on June 18, 2026
Option exercise price
$162.99 per share
Conversion or exercise price of stock options
Option expiration
June 18, 2036
Expiration date of Stock Option (Right to Buy)
Restricted stock units included
4,080 RSUs
RSUs included within reported holdings
Key Terms
restricted stock units, Stock Option (Right to Buy, exercise price, Service Provider, +1 more
5 terms
restricted stock units financial
"Includes 4,080 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy financial
"Stock Option (Right to Buy) with underlying Common Stock"
exercise price financial
"conversion_or_exercise_price: "162.9900" per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Service Provider financial
"subject to the Reporting Person remaining a Service Provider"
2020 Plan financial
"as defined in the 2020 Plan through the vesting date"
FAQ
What insider transactions did RVMD director Frank Clyburn report?
Frank Clyburn reported receiving 1,191 shares of Common Stock and 3,127 Stock Options (Right to Buy). These are equity awards, not open-market trades, and increase his direct position in Revolution Medicines.
What are the terms of Frank Clyburn’s new RVMD stock options?
Clyburn received 3,127 Stock Options with a $162.99 exercise price per share, expiring on June 18, 2036. Each option is exercisable for one share of Revolution Medicines common stock, following the vesting schedule described in the filing.
When do Frank Clyburn’s Revolution Medicines stock options vest?
The options vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the annual meeting following the grant date, provided he remains a Service Provider under the company’s 2020 Plan through that vesting date.
Are Frank Clyburn’s RVMD awards open-market purchases or compensation grants?
Both transactions are coded as A, indicating grants or awards. The common shares and options were granted at a reported price of $0.00 per share, reflecting equity compensation rather than open-market buying or selling of Revolution Medicines stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
